IDEXX Laboratories, Inc. (NASDAQ:IDXX) Chairman Jonathan W. Ayers sold 22,000 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $177.52, for a total value of $3,905,440.00. Following the completion of the sale, the chairman now owns 1,077,112 shares of the company’s stock, valued at $191,208,922.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at $172.95 on Friday. The company has a market capitalization of $14,764.38, a P/E ratio of 53.57, a PEG ratio of 2.08 and a beta of 0.58. IDEXX Laboratories, Inc. has a 12-month low of $140.63 and a 12-month high of $198.73. The company has a debt-to-equity ratio of -11.26, a current ratio of 0.97 and a quick ratio of 0.80.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.77 EPS for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.04. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The business had revenue of $506.00 million during the quarter, compared to analysts’ expectations of $490.51 million. During the same period in the previous year, the business earned $0.58 earnings per share. The business’s revenue was up 14.2% compared to the same quarter last year. sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 4.09 EPS for the current fiscal year.
IDXX has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective for the company in a research report on Tuesday, October 24th. Stifel Nicolaus restated a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, October 24th. BidaskClub cut IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. Piper Jaffray Companies initiated coverage on IDEXX Laboratories in a research report on Tuesday, January 16th. They issued an “overweight” rating and a $200.00 price objective for the company. Finally, Aegis restated a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $194.00.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.